Compare MRNA & MFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRNA | MFC |
|---|---|---|
| Founded | 2010 | 1887 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.2B | 73.2B |
| IPO Year | 2018 | 2002 |
| Metric | MRNA | MFC |
|---|---|---|
| Price | $199.18 | $42.22 |
| Analyst Decision | Hold | |
| Analyst Count | 23 | 0 |
| Target Price | ★ $164.53 | N/A |
| AVG Volume (30 Days) | ★ 11.4M | 1.2M |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 3.26% |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,263,000,000.00 | N/A |
| Revenue This Year | $24.09 | $91.93 |
| Revenue Next Year | $11.33 | N/A |
| P/E Ratio | ★ N/A | $16.52 |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $32.66 |
| 52 Week High | $280.80 | $46.19 |
| Indicator | MRNA | MFC |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 37.24 |
| Support Level | $181.02 | $41.62 |
| Resistance Level | $254.48 | $45.06 |
| Average True Range (ATR) | 17.92 | 0.78 |
| MACD | -7.14 | -0.25 |
| Stochastic Oscillator | 11.39 | 3.61 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Manulife Financial is one of the Big Three Canadian life insurers. The firm provides life insurance, annuities, asset management, and wealth management products to individuals and group customers in Canada, the United States, and Asia. The Canadian business segment contributes approximately 21% of 2025 adjusted earnings. The Asia segment operates across 12 countries and contributes around 38% of earnings, with a significant presence in Hong Kong and Singapore. The US business, which primarily operates under the John Hancock brand, contributes about 16% of earnings. Manulife's global asset and wealth management business contributes approximately 25% of its earnings. The firm had around CAD 1.2 trillion in assets under management and administration as of the end of June 2026.